Optiscan Imaging completes beta phase testing of cloud-based telepathology platform

Commercial-stage medical technology company Optiscan Imaging (ASX: OIL) has completed beta phase testing of its cloud-based telepathology platform developed in partnership with Prolucid Technologies.

The platform is believed to represent a significant advancement in digital pathology, enabling real-time collaboration on patient imaging sessions and allowing remote users to make immediate and informed decisions.

The phase tested its functionality and opened the way for enhanced patient imaging in remote scenarios.

Leveraging technology

The new platform leverages Optiscan’s confocal imaging technology to natively generate digital pathology data and empower remote pathologists and clinicians to collaborate in real-time during imaging sessions.

It streamlines the telepathology workflow with secure device-to-cloud connectivity and a dedicated web portal so that remote pathologists can seamlessly join the imaging session on a computer terminal and communicate their observations directly with the clinician.

The platform also allows for offline review and annotation of captured images, with detailed report generation planned for a future iteration.

Patient data privacy and secure user access are protected, with the architecture adhering to the highest regulatory and cybersecurity standards.

Informed decision-making

Optiscan managing director Dr Camile Farah said the technology facilitates fast and informed decision-making at the point of care and can ultimately improve patient outcomes.

“This platform is a potential game-changer for rural and remote patients who have traditionally lacked access to dedicated pathology expertise and immediate decision-making from clinicians and pathologists,” he said.

“Our platform provides a way for isolated communities to tap into pathology expertise previously not available to them due to limited medical infrastructure or difficulties in attracting health care professionals.”

Bridging the gap

Dr Farah said the beta testing was a milestone achievement in the platform’s development.

“It demonstrates that we have met our goal of creating a cloud-connected telepathology platform which bridges the gap between imaging and remote diagnostics, providing a seamless, secure and efficient workflow,” he said.

“With the beta testing phase now complete, we have ramped up efforts to create a commercial version of the platform and look forward to its implementation in clinical settings.”